Wide variability in rheumatoid arthritis drug suggests alternative dosing should be considered
November 4, 2008Methotrexate (MTX) is commonly used to treat rheumatoid arthritis (RA) and is suggested as the "anchor" drug in treating the disease. Despite its widespread use, the understanding of its mechanism of action and pharmacokinetics is limited. Since joint damage occurs early in the course of RA and is largely irreversible, understanding the time it takes for stable levels of MTX to be reached could be useful in effectively controlling RA and preventing long-term damage. A new study examining levels of MTX metabolites in red blood cells was published in the November issue of Arthritis & Rheumatism.
MTX is normally taken orally and is rapidly taken up into a variety of cells, including red blood cells, where it remains long after being eliminated from blood serum. Once inside red blood cells, the drug can assume up to five different forms, which are known as MTXGlu1-5 (MTX polyglutamates) These can be measured inside red blood cells and are thought to be representative of concentrations within other cells, such as lymphocytes. Within the cell, MTX polyglutamates bind to and inhibit several important enzymes, playing a role in a number of anti-inflammatory actions and pathways.
The dose of MTX varies and is unpredictable from patient to patient, but because it disappears rapidly from blood plasma, measurement in plasma can't be used to monitor concentrations of the drug. However, MTX polyglutamate concentrations can be measured in red blood cells. Patients with RA are normally started on low doses of MTX, with increasing amounts based on response to treatment, but valuable time may be lost with this method, resulting in unnecessary joint damage.
Led by Lisa Stamp and Murray Barclay of the University of Otago in Christchuch, New Zealand and supported by the Health Research Council of New Zealand, researchers examined the levels of MTX polyglutamates in the red blood cells of 10 patients who were beginning treatment with low-dose oral MTX and 10 patients who were stopping treatment. They used high-performance liquid chromatography to detect MTX polyglutamate concentrations in blood samples for an average of 40 weeks.
In most of the patients beginning therapy, the various forms of MTX polyglutamates were detectable in red blood cells between one and eight weeks following administration of the first dose. The median time until 90 percent of the maximum stable level of the drug was reached was 27.5 weeks. The authors note that starting with higher doses may cause some patients to discontinue therapy due to nausea. This might be avoided by injecting the drug, which has been shown to improve the clinical response at 24 weeks compared to oral therapy, but it is not known if this improvement occurred earlier compared to oral administration.
It took approximately 20 weeks for MTX polyglutamates to be undetectable in red blood cells. Elimination of the drug may be more rapid than accumulation due to the lifespan of red blood cells, which have a lifespan of about 120 days. As they gradually die out they are replaced with new cells which causes a "dilutional effect" when MTX is stopped. The lifespan of red blood cells may also contribute somehow to the delay in reaching stable levels of MTX polyglutamates. In any case, the fact that it takes so long for MTX to be eliminated after stopping treatment has implications for discontinuing it prior to surgery, conception and when an infection is present. "Although newly produced cells will not be exposed to MTX, existing cells will clearly continue to be affected by MTX for a considerable length of time," the authors note.
Although it was small, the study provides information as to how the different forms of MTX are accumulated and eliminated from red blood cells, which is quite variable and may limit the usefulness of MTX polyglutamates detection in these cells as an effective monitoring tool. The authors conclude that if MTX polyglutamate concentrations correlate with MTX efficacy, it may be necessary to consider either injecting the drug or rapidly increasing oral doses in order to reach stable levels.
Source: Wiley
-
Engineers build first sub-10-nm carbon nanotube transistor
Feb 01, 2012 |
4.9 / 5 (33) |
30
-
Something old, something new: Evolution and the structural divergence of duplicate genes
Jan 31, 2012 |
4.6 / 5 (7) |
1
-
The hidden nanoworld of ice crystals: Revealing the dynamic behavior of quasi-liquid layers
Jan 30, 2012 |
5 / 5 (4) |
1
-
Stock market network reveals investor clustering
Jan 27, 2012 |
3.9 / 5 (23) |
8
-
Of microchemistry and molecules: Electronic microfluidic device synthesizes biocompatible probes
Jan 26, 2012 |
5 / 5 (2) |
0
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
Overeating may double risk of memory loss
New research suggests that consuming between 2,100 and 6,000 calories per day may double the risk of memory loss, or mild cognitive impairment (MCI), among people age 70 and older. The study was released today and will be ...
Medicine & Health / Neuroscience
3 hours ago |
5 / 5 (2) |
0
|
Starve a virus, feed a cure? Findings show how some cells protect themselves against HIV
A protein that protects some of our immune cells from the most common and virulent form of HIV works by starving the virus of the molecular building blocks that it needs to replicate, according to research published online ...
6 hours ago |
5 / 5 (1) |
0
|
Declining health-care productivity in England: Who says so?
Reports that the National Health Service in England has been declining in productivity in the last decade appear to have been accepted as fact. However, a Viewpoint published Online First by The Lancet disputes this. The Vi ...
1 hour ago |
not rated yet |
0
Injured boomers beware: Know when to see doctor
(AP) -- It happened to nurse Jane Byron years after an in-line skating fall, business owner Haralee Weintraub while doing "men's" push-ups, and avid cyclist Gene Wilberg while lifting a heavy box.
8 hours ago |
5 / 5 (1) |
0
FDA-approved drug rapidly clears amyloid from the brain, reverses Alzheimer's symptoms in mice
Neuroscientists at Case Western Reserve University School of Medicine have made a dramatic breakthrough in their efforts to find a cure for Alzheimer's disease. The researchers' findings, published in the journal Science, show t ...
Medicine & Health / Neuroscience
Feb 09, 2012 |
4.9 / 5 (58) |
17
|
Scientists discover molecular secrets of 2,000-year-old Chinese herbal remedy
For roughly two thousand years, Chinese herbalists have treated Malaria using a root extract, commonly known as Chang Shan, from a type of hydrangea that grows in Tibet and Nepal. More recent studies suggest that halofuginone, ...
New method to examine batteries -- MRI from the inside
There is an ever-increasing need for advanced batteries for portable electronics, such as phones, cameras, and music players, but also to power electric vehicles and to facilitate the distribution and storage of energy derived ...
A mitosis mystery solved: How chromosomes align perfectly in a dividing cell
Although the process of mitotic cell division has been studied intensely for more than 50 years, Whitehead Institute researchers have only now solved the mystery of how cells correctly align their chromosomes during symmetric ...
Lab study raises questions over nano-particle impact
Tests involving chickens have raised questions about the impact on health from engineered nano-particles, the ultra-fine grains commonly used in drugs and processed foods, scientists said on Sunday.
Google might launch Drive for cloud storage soon
(PhysOrg.com) -- Google's next big move, according to the Wall Street Journal, is a cloud storage service called Drive. Hardly first to the plate, Google is simply catching up to introducing its cloud reposi ...
Researchers find extensive RNA editing in human transcriptome
In a new study published online in Nature Biotechnology, researchers from BGI, the world's largest genomics organization, reported the evidence of extensive RNA editing in a human cell line by analysis of RNA-seq data, demons ...